Affimed N.V EV/EBIT
What is the EV/EBIT of Affimed N.V?
The EV/EBIT of Affimed N.V. is N/A
What is the definition of EV/EBIT?
Enterprise value to earnings before interest and taxes (EV/EBIT) is a financial ratio used to measure if a stock is priced appropriately to similar stocks and the market. It is similar to the P/E ratio.
ttm (trailing twelve months)
The EV/EBIT ratio addresses some of the shortcomings of the P/E ratio. Instead of taking market capitalization, the ratio uses enterprise value, as it takes into account the true value of the company. Enterprise value includes both equity and debt. It is calculated as:
Enterprise value = market cap + total debt – cash and cash equivalents
The EV/EBIT ratio is useful in comparing peers within the wider market. A high EV/EBIT ratio indicates that a company’s stock is overvalued. On the opposite, a low EV/EBIT ratio indicates that a company’s stock is undervalued. The lower the ratio, the more financially stable a company should be. However, investors and analyst should use other ratios and information to get a full picture of a company’s financial state and actual value.
EV/EBIT of companies in the Health Care sector on NASDAQ compared to Affimed N.V
What does Affimed N.V do?
affimed (symbol: afmd) is a nasdaq-listed clinical-stage biopharmaceutical company focused on discovering and developing targeted immuno-oncology therapies. immuno-oncology represents a highly promising approach to cancer treatment that seeks to harness the body’s own immune defenses to attack and destroy tumor cells. natural killer cells, or nk-cells, and t-cells belong to the most potent cells of the human defense arsenal. affimed’s proprietary, next-generation bispecific antibodies, termed tandabs®, are designed to bring nk-cells or t-cells into close proximity to cancer cells that ultimately triggers a signal cascade that leads to the destruction of cancer cells. due to their novel tetravalent tandem architecture, which provides for four binding domains, the tandabs bind to specific targets on immune and cancer cells with high affinity. in addition, tandabs exhibit kinetic properties allowing the administration as regular intravenous infusion and fine-tuning of dosing. affimed beli
Companies with ev/ebit similar to Affimed N.V
- CytomX Therapeutics Inc has EV/EBIT of N/A
- Ansal Housing & Construction has EV/EBIT of N/A
- Teligent Inc has EV/EBIT of N/A
- MedinCell S.A has EV/EBIT of N/A
- ECR Minerals Plc has EV/EBIT of N/A
- Rincon Resources has EV/EBIT of N/A
- Affimed N.V has EV/EBIT of N/A
- Scienjoy has EV/EBIT of N/A
- Mafatlal Industries has EV/EBIT of N/A
- Indus has EV/EBIT of N/A
- King George has EV/EBIT of N/A
- Crossover Acquisitions has EV/EBIT of N/A
- Green Hygienics has EV/EBIT of N/A